Skip to main content
. 2019 May 3;70(6):1038–1047. doi: 10.1093/cid/ciz344

Table 2.

Comparisons of Study Cohort Characteristics by Intravenous Fluid Exposure

Characteristic IVF (n = 70) No IVF (n = 354) P Value
Age, y, mean (SD) 31.4 (20.6) 30.3 (18.3) .685
Sex .840
 Female 40 (57.1) 212 (59.9)
 Male 29 (41.4) 142 (40.1)
ETU location .314
 Bong County, Liberia 26 (37.4) 103 (29.1)
 Margibi County, Liberia 1 (1.4) 4 (1.1)
 Kambia District, Sierra Leone 2 (2.9) 31 (8.8)
 Port Loco District, Sierra Leone 21 (30.0) 127 (35.9)
 Bombali District, Sierra Leone 20 (28.6) 89 (25.1)
Cycle threshold value .027
 Low (≤22) 23 (32.9) 136 (38.4)
 High (>22) 14 (20) 108 (30.5)
 Missing 33 (47.1) 110 (31.1)
Patients with clinical characteristics during ETU admission
 Anorexia 48 (68.6) 294 (83.1) .017
 Any bleeding 24 (34.3) 174 (49.2) .018
 Coma 1 (1.4) 41 (11.6) .000
 Confusion 3 (4.3) 53 (15) .007
 Diarrhea 48 (68.6) 315 (89) .001
 Dysphagia 31 (44.3) 218 (61.6) .009
 Dyspnea 28 (40.0) 175 (49.4) .205
 Fever 51 (72.9) 273 (77.1) .435
 Stomach pain 48 (68.6) 277 (78.2) .100
 Vomiting 41 (58.6) 283 (79.9) .001
Patients receiving treatment during ETU admission
 Acetaminophen 59 (84.3) 350 (98.9) .003
 Artemether 0 (0.0) 18 (5.1) .049
 Artemether-lumefantrine 58 (82.9) 322 (91.0) .094
 Artesunate 0 (0.0) 23 (6.5) .010
 Cefixime 56 (80.0) 332 (93.8) .013
 Ceftriaxone 0 (0.0) 95 (26.8) .000
 Ciprofloxacin 0 (0.0) 30 (8.5) .001
 Metoclopramide 7 (10.0) 115 (32.5) .000
 Metronidazole 0 (0.0) 16 (4.5) .066
 Multivitamins 38 (54.3) 275 (77.7) .000
 Omeprazole 56 (80.0) 338 (95.5) .005
 Ondansetron 3 (4.3) 170 (48.0) .000
 Oral rehydration solution 59 (84.3) 345 (97.5) .003
 Promethazine 0 (0.0) 8 (2.3) .003
 Vitamin A 49 (70.0) 307 (86.7) .004
 Vitamin C 56 (80.0) 341 (96.3) .001
 Zinc sulphate 4 (5.7) 49 (13.8) .056

Data are presented as no. (%) unless otherwise indicated.

Abbreviations: ETU, Ebola treatment unit; IVF, intravenous fluid; SD, standard deviation.